» Articles » PMID: 25761508

Type 2 Diabetes and Cardiac Autonomic Neuropathy Screening Using Dynamic Pupillometry

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2015 Mar 13
PMID 25761508
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To determine if changes in pupillary response are useful as a screening tool for diabetes and to assess whether pupillometry is associated with cardiac autonomic neuropathy.

Methods: We conducted a cross-sectional study with participants drawn from two settings: a hospital and a community site. At the community site, individuals with newly diagnosed diabetes as well as a random sample of control individuals without diabetes, confirmed by oral glucose tolerance test, were selected. Participants underwent an LED light stimulus test and eight pupillometry variables were measured. Outcomes were diabetes, defined by oral glucose tolerance test, and cardiac autonomic dysfunction, determined by a positive readout on two of four diagnostic tests: heart rate response to the Valsalva manoeuvre; orthostatic hypotension; 30:15 ratio; and expiration-to-inspiration ratio. The area under the curve, best threshold, sensitivity and specificity of each pupillometry variable was calculated.

Results: Data from 384 people, 213 with diabetes, were analysed. The mean (±sd) age of the people with diabetes was 58.6 (±8.2) years and in the control subjects it was 56.1 (±8.6) years. When comparing individuals with and without diabetes, the amplitude of the pupil reaction had the highest area under the curve [0.69 (sensitivity: 78%; specificity: 55%)]. Cardiac autonomic neuropathy was present in 51 of the 138 people evaluated (37.0%; 95% CI 28.8-45.1). To diagnose cardiac autonomic neuropathy, two pupillometry variables had the highest area under the curve: baseline pupil radius [area under the curve: 0.71 (sensitivity: 51%; specificity: 84%)], and amplitude of the pupil reaction [area under the curve: 0.70 (sensitivity: 82%; specificity: 55%)].

Conclusions: Pupillometry is an inexpensive technique to screen for diabetes and cardiac autonomic neuropathy, but it does not have sufficient accuracy for clinical use as a screening tool.

Citing Articles

Measuring the Pupillary Light Reflex Using Portable Instruments in Applied Settings.

Gray N, Price M, Pink J, OConnor C, Antunes A, Snowden R Vision (Basel). 2024; 8(4).

PMID: 39449393 PMC: 11503361. DOI: 10.3390/vision8040060.


Characterising cerebrovascular reactivity and the pupillary light response-a comparative study.

Sparks S, Hayes G, Pinto J, Bulte D Front Physiol. 2024; 15:1384113.

PMID: 39175613 PMC: 11338921. DOI: 10.3389/fphys.2024.1384113.


Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management.

Eleftheriadou A, Spallone V, Tahrani A, Alam U Diabetologia. 2024; 67(12):2611-2625.

PMID: 39120767 PMC: 11604676. DOI: 10.1007/s00125-024-06242-0.


Basics, benefits, and pitfalls of pupillometers assessing visual function.

Philibert M, Milea D Eye (Lond). 2024; 38(12):2415-2421.

PMID: 38802485 PMC: 11306737. DOI: 10.1038/s41433-024-03151-9.


The impact of Alzheimer's disease risk factors on the pupillary light response.

Sparks S, Pinto J, Hayes G, Spitschan M, Bulte D Front Neurosci. 2023; 17:1248640.

PMID: 37650103 PMC: 10463762. DOI: 10.3389/fnins.2023.1248640.


References
1.
Hu D, Fu P, Xie J, Chen C, Yu D, Whelton P . Increasing prevalence and low awareness, treatment and control of diabetes mellitus among Chinese adults: the InterASIA study. Diabetes Res Clin Pract. 2008; 81(2):250-7. DOI: 10.1016/j.diabres.2008.04.008. View

2.
Vinik A, Erbas T . Cardiovascular autonomic neuropathy: diagnosis and management. Curr Diab Rep. 2006; 6(6):424-30. DOI: 10.1007/s11892-006-0074-z. View

3.
. Standards of medical care in diabetes--2013. Diabetes Care. 2012; 36 Suppl 1:S11-66. PMC: 3537269. DOI: 10.2337/dc13-S011. View

4.
Wu A, Kong N, de Leon F, Pan C, Tai T, Yeung V . An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia. 2004; 48(1):17-26. DOI: 10.1007/s00125-004-1599-9. View

5.
El Feghali R, Topouchian J, Pannier B, El Assaad H, Asmar R . Validation of the OMRON M7 (HEM-780-E) blood pressure measuring device in a population requiring large cuff use according to the International Protocol of the European Society of Hypertension. Blood Press Monit. 2007; 12(3):173-8. DOI: 10.1097/MBP.0b013e3280b08367. View